News | July 31, 2021
Zydus Wellness Q1FY22 consolidated net profit at Rs. 130.80 Cr
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The drug is used with other HIV medications to help control HIV infection and it helps to decrease the amount of HIV in one’s body so that the immune system can work better
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Subscribe To Our Newsletter & Stay Updated
